Marapsin-1 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Marapsin-1 (PRSS27/Q9BQR3), expressed in HEK293 cells. Suitable for serine protease activity assays, inhibitor profiling, and antibody validation studies.
Expression system
HEK293
Cat. #
REC-Marapsin1

In stock

SKU
REC-Marapsin1
$498.00

Target Overview

Marapsin-1 (gene: PRSS27; UniProt: Q9BQR3) is a secreted serine protease of 290 amino acids classified under EC 3.4.21.-. Also known as Pancreasin, it belongs to the chymotrypsin-like serine protease superfamily and is notable for its expression in stratified squamous epithelia and a subset of glandular tissues, including pancreas. The protein is predicted to be processed from a zymogen precursor to a catalytically active form following secretion. This recombinant is produced in HEK293 mammalian cells, an expression system well suited for serine proteases that require eukaryotic post-translational processing — including signal peptide cleavage, disulfide bond formation, and N-linked glycosylation — to adopt a native-like conformation. HEK293-derived material is therefore preferred over prokaryotic expression for activity-dependent applications. The recombinant spans the full 290-residue sequence of the human PRSS27 protein. In the laboratory, this recombinant protein is primarily used in three contexts. First, in enzymatic activity assays employing fluorogenic peptide substrates (e.g., Suc-AAPF-AMC or related chymotrypsin-type substrates) to characterise catalytic parameters such as Km and kcat. Second, in small-molecule inhibitor screens and IC50 determinations, where a defined, active enzyme preparation is essential for reproducible dose-response measurements. Third, as a positive-control antigen for antibody validation: researchers loading a known quantity of this recombinant onto SDS-PAGE can confirm band specificity for anti-PRSS27 antibodies in Western blot and IHC workflows. For the latter application, this recombinant can be paired directly with Triple Point Biologics' matched anti-Marapsin-1 antibody (SKU: RP-Marapsin1), validated for Western blot against human tissue, with predicted cross-reactivity to mouse, pan-primate, monkey, and dog.

Background

Marapsin-1 (PRSS27) is a secreted chymotrypsin-like serine protease whose biology has attracted growing interest across multiple research areas, from epithelial tissue remodeling to metabolic disease and cancer. Early characterisation identified PRSS27 expression in pancreatic acinar cells — accounting for the synonym Pancreasin — and in stratified squamous epithelia such as esophageal and skin tissue. This epithelial enrichment placed Marapsin-1 in the broader context of kallikrein-related and TTSP-family proteases implicated in extracellular matrix remodeling, desquamation, and epithelial barrier function. Its designation as "Marapsin" reflects its expression pattern in the oral mucosa and related sites. More recently, PRSS27 has been studied as a research target in oncology. Wang Z et al. (2025, Life Sci, PMID: 40816503) reported that PRSS27 expression is driven by super-enhancer activity in lung adenocarcinoma, where it was found to attenuate oxidative stress and apoptosis through activation of the PI3K/AKT signaling pathway. This study positions PRSS27 as a transcriptionally regulated effector in lung cancer cell survival, making enzymatically active recombinant Marapsin-1 a useful tool for mechanistic follow-up experiments, including substrate identification and pathway-interaction studies. Beyond oncology, PRSS27 has appeared as a candidate in proteomics-based biomarker discovery. Yimei H et al. (2026, Int J Cardiol Heart Vasc, PMID: 42112507) identified PRSS27 among novel candidate biomarkers for heart failure with preserved ejection fraction (HFpEF) using the Olink proximity extension assay platform, illustrating the protein's potential utility as a circulating analyte in cardiovascular research. In a separate proteomics study, Zhang F et al. (2025, Clin Rheumatol, PMID: 40439986) implicated PRSS27 in the identification of putative therapeutic targets for psoriatic arthritis. Marapsin-1 has also been detected in studies of hormone-responsive mucosal tissues: Tomczyk K et al. (2026, Sci Rep, PMID: 42156451) reported PRSS27 modulation in human vaginal mucosa following prasterone therapy, in the context of steroid receptor-driven extracellular matrix remodeling. Collectively, these published datasets establish Marapsin-1 as a research target spanning epithelial biology, cancer signaling, and cardiometabolic proteomics — all contexts in which a well-characterized, mammalian-expressed recombinant protein is a practical experimental tool.

Applications

  • Fluorogenic peptide substrate cleavage assay (e.g., Suc-AAPF-AMC) to determine Km, kcat, and catalytic efficiency
  • Small-molecule serine protease inhibitor screening and IC50 determination by continuous fluorescence readout
  • Antibody validation positive control: recombinant antigen loaded on SDS-PAGE for Western blot band confirmation alongside anti-Marapsin-1 antibody (RP-Marapsin1)
  • IHC antibody titration standard: spike-in recombinant to confirm signal specificity for anti-PRSS27 reagents
  • Substrate identification by mass spectrometry: incubation with candidate peptide or protein substrates to define cleavage specificity
  • Binding affinity measurement (SPR or BLI) with candidate inhibitors, natural substrates, or interaction partners
  • PI3K/AKT pathway mechanistic studies: recombinant enzyme used to probe PRSS27-dependent cell signaling in lung epithelial cell models
  • Olink/proximity-extension assay calibration and cross-reactivity testing for PRSS27 in plasma proteomics workflows

References

  1. Tomczyk K et al. Short-term vaginal prasterone therapy induces steroid receptor modulation and extracellular matrix remodeling in human vaginal mucosa. Sci Rep. 2026. doi:10.1038/s41598-026-50491-5. PMID: 42156451.
  2. Yimei H et al. Identification of novel candidate biomarkers for heart failure with preserved ejection fraction by the Olink proteomics platform. Int J Cardiol Heart Vasc. 2026. doi:10.1016/j.ijcha.2025.101859. PMID: 42112507.
  3. Wang Z et al. Upregulation of PRSS27 driven by super-enhancers attenuates oxidative stress and apoptosis via activating PI3K/AKT pathway in lung adenocarcinoma. Life Sci. 2025. doi:10.1016/j.lfs.2025.123903. PMID: 40816503.
  4. Zhao Z et al. CRP and HNF1A collaborate to regulate the progression of laryngeal cancer through the Wnt signaling pathway. Funct Integr Genomics. 2025. doi:10.1007/s10142-025-01670-6. PMID: 40715562.
  5. Zhang F et al. Identification of therapeutic targets for psoriatic arthritis through proteomics. Clin Rheumatol. 2025. doi:10.1007/s10067-025-07508-7. PMID: 40439986.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Subcellular localization not yet annotated

Frequently Asked Questions

What molecular weight should I expect for recombinant Marapsin-1 on SDS-PAGE or Western blot?

The human PRSS27 open reading frame encodes 290 amino acids, giving a predicted unglycosylated MW of approximately 32 kDa. Because this recombinant is produced in HEK293 cells, N-linked glycosylation adds mass, so the predominant band on reducing SDS-PAGE typically runs at 35–42 kDa. Under non-reducing conditions, disulfide-dependent compaction can shift apparent mobility slightly. If you are running a Western blot positive control alongside RP-Marapsin1, expect the band in the 35–42 kDa window; load 50–100 ng per lane for a clean, unambiguous signal.

Is recombinant Marapsin-1 supplied as a zymogen or as the mature active form of PRSS27?

PRSS27 is natively secreted as a zymogen and undergoes proteolytic cleavage of its propeptide to yield the catalytically active serine protease. The REC-Marapsin1 recombinant is produced in HEK293 cells under conditions that favor secretion-coupled processing, and the material is supplied as the active enzyme form. That said, propeptide cleavage efficiency can vary batch to batch — the Certificate of Analysis specifies the processing status and includes an activity confirmation using a fluorogenic substrate. If zymogen-to-enzyme conversion is critical to your assay design, contact us for the lot-specific data before ordering.

What substrates does Marapsin-1 cleave, and what fluorogenic substrate should I use for an activity assay?

Marapsin-1 is a chymotrypsin-like serine protease (EC 3.4.21.-), meaning it preferentially cleaves after bulky hydrophobic residues — phenylalanine, tyrosine, and leucine. For fluorogenic activity assays, Suc-Ala-Ala-Pro-Phe-AMC is a well-validated chymotrypsin-like substrate and provides a strong signal with this enzyme class. Alternatively, Z-Phe-Arg-AMC can be tested if you wish to probe broader specificity. Run reactions at 37°C in 50 mM Tris-HCl pH 7.5, 150 mM NaCl — matching the storage buffer — and monitor fluorescence at Ex 380 nm / Em 460 nm. Include a serine protease inhibitor control (e.g., PMSF or AEBSF) to confirm signal specificity.

What buffer conditions and starting enzyme concentration should I use for a Marapsin-1 protease activity assay?

Start in 50 mM Tris-HCl pH 7.5, 150 mM NaCl — this matches the storage buffer, so no buffer-exchange step is required for initial characterization. A starting enzyme concentration of 1–5 nM is reasonable for fluorogenic substrate assays using Suc-Ala-Ala-Pro-Phe-AMC at 100 µM substrate. Optimize pH between 7.0–8.5 if you need to mimic a specific tissue microenvironment; chymotrypsin-like proteases are generally most active at slightly alkaline pH. Avoid Ca²⁺ chelators such as EDTA unless you are intentionally testing ionic effects. Include 0.01% BSA to minimize non-specific adsorption to low-binding plates.

How do I set up an inhibitor IC50 assay with recombinant Marapsin-1, and what controls should I include?

For IC50 determination, use 1–2 nM REC-Marapsin1 and 100 µM Suc-Ala-Ala-Pro-Phe-AMC in 50 mM Tris-HCl pH 7.5, 150 mM NaCl. Pre-incubate enzyme with inhibitor for 30 minutes at room temperature before adding substrate to allow equilibration, particularly for slow-binding inhibitors. Measure initial velocity (first 5–10 minutes of linear phase) rather than endpoint fluorescence. Include PMSF or AEBSF as a positive inhibition control (complete inhibition expected at 1 mM), substrate-only blank, and enzyme-only vehicle control. Fit velocity-vs.-concentration data to a four-parameter logistic model to extract IC50.

Can I use REC-Marapsin1 as a Western blot positive control for the RP-Marapsin1 rabbit polyclonal antibody?

Yes — this is one of the primary intended uses of REC-Marapsin1. The RP-Marapsin1 rabbit polyclonal antibody (catalog /anti-marapsin-1-rabbit-polyclonal-antibody) was raised against the same PRSS27 sequence used for this recombinant, so epitope compatibility is guaranteed. Load 50–100 ng of REC-Marapsin1 per lane alongside your experimental lysates; expect a band at 35–42 kDa given HEK293-derived glycosylation. This pairing is also useful for antibody lot-to-lot validation: consistent band intensity and mobility across lots confirms antibody performance without relying on variable endogenous expression in cell lines.

How much recombinant Marapsin-1 should I load per lane for a Western blot positive control, and what dilution of RP-Marapsin1 antibody should I use?

Load 50–100 ng of REC-Marapsin1 per lane for a strong, clean positive control band at 35–42 kDa. For the matched RP-Marapsin1 rabbit polyclonal antibody, a primary antibody dilution of 1:500–1:2,000 in 5% non-fat milk or 3% BSA/TBST is a practical starting range for Western blot; optimize for your blocking reagent and membrane type. Because the recombinant is >90% pure by SDS-PAGE and the antibody was generated against the same PRSS27 construct, background from off-target bands is minimal at these dilutions. Reduce antibody concentration if background is high, rather than reducing protein load.

How should I store recombinant Marapsin-1, and what is its expected shelf life after thawing?

REC-Marapsin1 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol and shipped on dry ice. Store at -20°C in the single-use aliquots provided. Avoid repeated freeze-thaw cycles — each cycle can reduce serine protease activity by 10–20% through denaturation and aggregation. Once thawed, keep on ice and use within 4–8 hours; do not refreeze a working aliquot. Under correct storage, activity and integrity are stable for 12 months from the date of receipt. If you anticipate using the protein across multiple sessions, prepare smaller working aliquots immediately after the first thaw.

Validation imagery coming soon

Western blot validation figures for REC-Marapsin1 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →